Form 8-K - Current report:
SEC Accession No. 0000950170-25-074428
Filing Date
2025-05-19
Accepted
2025-05-19 16:36:37
Documents
15
Period of Report
2025-05-19
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K crsp-20250519.htm   iXBRL 8-K 79741
2 EX-5.1 crsp-ex5_1.htm EX-5.1 70849
3 EX-10.1 crsp-ex10_1.htm EX-10.1 200495
4 GRAPHIC img33470342_0.jpg GRAPHIC 4958
5 GRAPHIC img33470342_1.jpg GRAPHIC 3082
6 GRAPHIC img170270991_0.jpg GRAPHIC 256716
  Complete submission text file 0000950170-25-074428.txt   1153940

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250519.xsd EX-101.SCH 25971
17 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250519_htm.xml XML 4500
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37923 | Film No.: 25964549
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)